The patient is in a stable phase of CML (cytogenetic response, ratio BCR-ABL1/ABL1 = 1% or lower expressed on the international scale, stable lymphocyte counts >1,500 μl. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.